Editorial 薬価問題の解決策の展開 2016年12月1日 Nature Biotechnology 34, 12 doi: 10.1038/nbt.3748 Despite an increasingly strident outcry against drug prices in the United States, manufacturers likely face an evolution in the reimbursement landscape, rather than a revolution. Full text PDF 目次へ戻る
